

Iconovo Q2 - Soft sales but costs under control

Redeye provides an update following Iconovo's Q2 report. The report itself did not include any major surprises, in our view. However, we learned that the company is in ongoing negotiations regarding an ICOpri licensing deal. We expect a deal during Q3 and argue it is a solid near-term catalyst for the share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Iconovo Q2 - Soft sales but costs under control](#)